ESMO WCGIC 2021 | Liquid biopsies in mCRC

Paolo Manca, MD, Istituto Nazionale dei Tumori Milano, Milano, Italy explains that liquid biopsy is being used more frequently to measure disease burden through circulating tumor cells in metastatic colorectal cancer (mCRC), with this increase in popularity correlating with the decreasing cost of next-generation sequencing (NGS). Future research may focus on maximizing the use of liquid biopsy in mCRC, for example, by using a wider gene panel during analysis to achieve more accurate ctDNA measurement. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.